COVID-19：Emergency response measures for GCP in Hunan province under the first level response of major public health emergencies（2.0 Version）

doi:10.12092/j.issn.1009-2501.2020.03.013

Abstract

CLC Number:

QIN Qun, LIU Xiaobao, YANG Guoping, LI Zhuo, LI Kunyan, HUANG Zhijun, LIU Zhaoqian. COVID-19：Emergency response measures for GCP in Hunan province under the first level response of major public health emergencies（2.0 Version）[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 323-328.

References

［1］中华人民共和国国家卫生健康委员会.国家卫生健康委关于修订新型冠状病毒肺炎英文命名事宜的通知［EB/OL］.［2020-0222］.http://www.nhc.gov.cn/yzygj/s7653p/202002/33393aa53d984ccdb10
53a52b6bef810.shtml
［2］疾病预防控制局.中华人民共和国国家卫生健康委员会公告(2020年第1号)［EB/OL］. ［2020-01-20］.http://www.nhc.gov.cn/xcs/zhengcwj/202001/44a3b8245e8049d2837a4f27529cd386.shtml.
［3］Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study［J］. The Lancet, 2020, doi:10.1016/S0140-6736(20)30260-30269.
［4］中华人民共和国国家卫生健康委员会.新型冠状病毒肺炎防控方案（第五版）［EB/OL］.［2020-02-21］.http://www.nhc.gov.cn/jkj/s3577/202002/a5d6f7b8c48c451c87dba14889b30147.shtml
［5］Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding［J］. The Lancet, 2020, doi:10.1016/S0140-6736(20)30251-8.
［6］Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin［J/OL］. Nature, 2020, https://doi.org/10.1038/s41586-020-2012-7.
［7］中华人民共和国国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第六版) ［EB/OL］.［2020-02-19］. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml
［8］国务院应对新型冠状病毒感染肺炎疫情联防联控机制.企事业单位复工复产疫情防控措施指南［EB/OL］.［2020-02-22］.http://www.nhc.gov.cn/zyjks/gongw/202002/e6dad55e209a4a46b9f003cd060
80997.shtml
［9］中华人民共和国中央人民政府.李克强主持召开中央应对新型冠状病毒感染肺炎疫情工作领导小组会议部署进一步有针对性加强疫情防控工作要求有序做好恢复生产保障供应工作［EB/OL］. ［2020-02-06］. http://www.gov.cn/premier/2020-02/06/content_5475409.html
［10］湖南省人民政府.杜家毫主持召开省委新冠肺炎疫情防控工作领导小组会议［EB/OL］. ［2020-02-11］. http://www.hunan.gov.cn/hnszf/hnyw/sy/hnyw1/202002/t20200212_11176745.html
［11］中华人民共和国国家卫生健康委员会.职业健康技术服务机构新冠肺炎疫情防控工作指引［EB/OL］. ［2020-02-14］. http://www.nhc.gov.cn/zyjks/s7788/202002/73b66eed6093443daae0a36c3de774b
5.shtml

[1]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[2]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[3]	DAI Jiahui, SUN Sijia, XIE Xuefeng. Quality management and indicator system for clinical trials of medical devices [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
[4]	CHEN Jianfang, LOU Donghua. Design of case report form for oncology clinical trials based on CDASH [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
[5]	LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin. Ethical analysis and countermeasures of artificial intelligence application in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
[6]	ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li. Clinical trials of inhalation in pediatric population in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
[7]	LI Shanshan, GU Jingwen, ZHANG Jing, YANG Haijing, LIU Wei, YU Yiqi, ZHANG Wenhong. Design and evaluation of clinical trials of COVID-19 vaccine and monoclonal neutralizing antibody [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 190-197.
[8]	TANG Jiawei, MENG Xiangzhe, SUN Xuemin, LI Yuexuan, LIU Xue, WEI Hong. Role of vitamin D and ACE2 in COVID-19 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1292-1298.
[9]	DENG Kunhong, LIU Yaxin, SUN Yuanyuan, CHEN Wenjing, YANG Nan, HU Zhanqing, CHEN Kaifeng, HUANG Jie, XIANG Yuxia, YANG Guoping. Literature analysis of the design and results of the First-In-Human clinical trials of drugs from 2009 to 2020 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 77-85.
[10]	ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
[11]	SHE Zhihua, CHEN Zhou, LIANG Songyue. Construction of informatization system of drug clinical trials ethical review based on cloud architecture [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030.
[12]	SONG Yan, GAO Linyan, ZHANG Yanping, LI Xiang, ZHANG Lan. Application of medical failure mode and effect analysis in blood sample management in phase I clinical trials#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1031-1036.
[13]	OUYANG Chenxi, HUANG Jie, XIANG Yuxia, WANG Xiaomin. Ethical issues and countermeasures of early phase trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 802-807.
[14]	HUANG Lihong, WANG Ling, YAN Fangrong, WEI Zhaohui, ZHAO Yang, XIA Jielai, CHEN Feng. New perspectives on the principle of intention to treat in clinical trials#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 449-453.
[15]	Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.